GH Research (NASDAQ:GHRS) Trading 4.9% Higher - What's Next?

GH Research PLC (NASDAQ:GHRS - Get Free Report) rose 4.9% on Thursday . The stock traded as high as $13.21 and last traded at $12.66. Approximately 39,796 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 163,339 shares. The stock had previously closed at $12.06.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Royal Bank of Canada started coverage on GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 target price on the stock. Guggenheim assumed coverage on shares of GH Research in a report on Thursday, March 13th. They set a "buy" rating and a $32.00 price target for the company. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Cantor Fitzgerald assumed coverage on GH Research in a research note on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price target on the stock. Finally, Stifel Nicolaus upped their price objective on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research has an average rating of "Buy" and a consensus price target of $30.86.

GH Research Stock Down 0.3 %

The company has a market cap of $573.87 million, a P/E ratio of -13.96 and a beta of 0.94. The firm's 50 day moving average is $11.76 and its two-hundred day moving average is $9.36.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. As a group, research analysts forecast that GH Research PLC will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. increased its position in shares of GH Research by 1.3% during the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock worth $44,734,000 after buying an additional 85,000 shares during the period. Millennium Management LLC acquired a new stake in GH Research during the 4th quarter worth about $145,000. Two Sigma Investments LP bought a new position in shares of GH Research in the 4th quarter worth about $117,000. BNP Paribas Financial Markets bought a new position in shares of GH Research in the 4th quarter worth about $44,000. Finally, Northern Trust Corp boosted its position in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).